We can now simulate that. So with this system, one of the things that this AlphaFold three can do is predict what molecules will bind and promote certain sequences of DNA, which is exactly what we try and do with the Yamanaka factor based expression systems and find ones that won't trigger off target expression. So meaning we can now go through the search space in software of creating a combination of molecules that theoretically could unlock this fountain of youth to de-age all the cells in the body and introduce an extraordinary kind of health benefit.
As of November 30, 2025, this prediction is about a long‑term future capability and clinical impact, and there is not yet enough time or evidence to say it is clearly right or clearly wrong.
What has happened so far
-
AlphaFold 3 and related models can model complex interactions, but mainly in silico and preclinical contexts.
- DeepMind/Isomorphic Labs’ AlphaFold 3 (2024) extends structure prediction to protein–protein, protein–DNA/RNA, and protein–ligand complexes, improving the ability to model binding interactions across chemical space.
- However, these are prediction tools, not validated end‑to‑end drug‑discovery pipelines that guarantee safe, specific reprogramming of human cells.
-
In‑silico search over chemical and biological space is real and rapidly improving.
- Many groups and companies now use generative and predictive models (including structure predictors like AlphaFold, diffusion models, and reinforcement learning) to design small molecules, biologics, and RNA constructs. Some are applied to aging-related pathways or senolytics in preclinical work.
- These tools support exploration of candidates but do not yet reliably deliver clinically proven longevity or rejuvenation therapies.
-
Yamanaka‑factor / partial reprogramming for rejuvenation is still preclinical.
- There is active research using OSKM and related factors for cellular rejuvenation and partial reprogramming in mice and cell culture, and several startups (e.g., Altos Labs, NewLimit, etc.) are pursuing this area.
- As of 2025, there is no approved human therapy that safely “de‑ages all the cells in the body” using Yamanaka‑style reprogramming, and no widely accepted clinical protocol derived from an AlphaFold‑like in‑silico combinatorial search.
Why the prediction is “inconclusive” rather than wrong
- The claim is essentially that in the future, systems like AlphaFold 3 will let us computationally search over combinations of molecules that can safely reprogram cells and unlock powerful rejuvenation/longevity therapies.
- This is a directional, long‑horizon forecast about what will be possible, not about something that should already have occurred by 2025.
- Current evidence shows early enabling steps (powerful structure prediction, AI‑assisted design, active partial‑reprogramming research), but not the end state (validated, safe, clinically deployed rejuvenation therapies discovered this way).
Because the timeframe is open‑ended and the core claim concerns capabilities and therapies that plausibly lie decades away, it is too early to judge it as right or wrong. Hence the status is “inconclusive (too early)”.